Every peptide, mapped to the body.

153 peptides, from approved drugs to compounds still in trials, sorted by where they act.

FDA-approved
In clinical trials
Wellness and performance
Cosmetic and topical

Loading the body

In clinical trials

Digestive & weight

Brilacidin

EvidenceLow research

ClassDefensin-mimetic host-defense peptide

Brilacidin is an investigational defensin-mimetic studied for oral mucositis and infections. Learn how it works, what research shows, and its approval status.

Reviewed by: William Maish, MD MBA MPH, Clinical Product Lead
Published: October 5, 2026
Last updated: October 5, 2026

Key takeaway

Brilacidin is an investigational defensin-mimetic, a small molecule designed to imitate the body's own host-defense peptides, developed by Innovation Pharmaceuticals for oral mucositis and studied as an antibacterial and antiviral agent. Its human results to date have been reported mainly through company announcements rather than peer-reviewed trials, while published support is largely laboratory-based. As of 2026 it is not approved for any use.

At a glance

FDA status	Investigational defensin-mimetic, not approved by the FDA for any use
Main uses	Being studied for oral mucositis, bacterial infections, and antiviral uses
Human evidence	Peer-reviewed human efficacy data are lacking; positive results are company-reported
Research	Published support mostly laboratory and preclinical
Evidence strength	Low research

What is brilacidin?

Brilacidin (brilacidin tetrahydrochloride) is an experimental compound designed to mimic defensins, the naturally occurring host-defense peptides that help fight microbes. It is technically a peptide-mimetic (a small molecule built to reproduce defensin biology) rather than a true peptide. Developed by Innovation Pharmaceuticals under the code PMX-30063, it has been studied as a mouth rinse for oral mucositis and as a potential antibacterial and antiviral treatment. Brilacidin is investigational and not approved.

How does it work?

Brilacidin's proposed actions differ by target:

Bacteria and fungi: its structure carries a pattern of charge that lets it interact with and disrupt microbial membranes, the proposed basis for its antibacterial and antifungal activity
Viruses: in laboratory studies against SARS-CoV-2¹, it has been reported to disrupt the virus and interfere with how it enters cells
Oral mucositis: an anti-inflammatory action has been proposed

These are mechanisms observed mainly in the laboratory, separate from whether the drug helps patients.

Is it FDA-approved?

No. Brilacidin is investigational across all its studied uses and is not approved. Development has been slow and dependent on partnering and funding, and no confirmatory Phase 3 has been reported as completed.

What does the research show?

The published human evidence is limited, and according to PubMed, the peer-reviewed literature is mainly laboratory work. The table sorts the evidence by type:

Evidence	Setting	Reported result	Peer-reviewed
Oral mucositis Phase 2 trial	Human	Described by the company as positive, in a press-release topline	No
COVID-19 Phase 2 trial	Human	Described by the company as positive, in a press-release topline	No
Laboratory study	Cell culture	Brilacidin inhibits SARS-CoV-2¹	Yes
Laboratory study	Laboratory	Shows broad antiviral activity² against coronaviruses	Yes

Without peer-reviewed controlled human efficacy data, its clinical benefit is unestablished.

More for digestive & weight

Sources: laboratory studies of brilacidin against SARS-CoV-2 (Bakovic et al., Viruses, 2021, DOI: 10.3390/v13020271¹; Hu et al., Journal of Medical Virology, 2022, DOI: 10.1002/jmv.27616²), both indexed on PubMed; and Innovation Pharmaceuticals program updates. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.